Astrea Bioseparations (“Astrea Bio”), a number one provider of high-quality bioseparation and purification technologies, announced today the acquisition of Delta Precision Ltd. (“Delta Precision”), a premier manufacturer of advanced chromatography columns for the biotechnology and pharmaceutical industries.

This strategic acquisition, which follows a long-standing relationship of virtually a decade, will allow Astrea Bio to expand its product offering to incorporate a full range of high-performance chromatography columns for biomanufacturing, complementing and strengthening the corporate’s existing portfolio of bioprocessing resins, reusable columns, and prepacked single-use columns. Delta Precision’s products are widely known for his or her quality, ease of use, and sturdiness, and are utilized in quite a lot of applications, including protein purification, vaccine production, and drug development.

We’re delighted to welcome the Delta team into the fold. The acquisition of Delta is one other step forward in Astrea Bio’s rapid expansion to support the biopharmaceutical manufacturing field. It is a highly strategic move for us, allowing us to supply a full range of industry-leading purification and separation tools.”

Terry Pizzie, CEO, Astrea Bio

Geoff Parnell, Co-founder and Managing Director at Delta Precision, remarked, “We sit up for joining the Astrea Bio family, further cementing the long-standing relationship between the 2 corporations. We’re confident that our expertise in column manufacturing will complement and speed up the Astrea Bio business and customer reach.”

This acquisition marks a big milestone for Astrea Bioseparations and can allow the corporate to further speed up latest product development and rapidly bring latest advances in purification and separation technology to market.